MedTrace Logo

Remimazolam on the Incidence of Postoperative Acute Kidney Injury

NCT07674719 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 78

Last updated 2026-06-29

No results posted yet for this study

Summary

We hypothesized that in patients undergoing elective hepatobiliary-pancreatic surgery, the group in which anesthesia is induced and maintained with remimazolam during surgery would maintain hemodynamic stability and reduce the incidence of postoperative acute kidney injury compared to propofol. The purpose is to provide practical evidence for perioperative management differentiated from other surgeries for hepatobiliary-pancreatic surgery patients for whom intraoperative fluid therapy is restricted.

Conditions

  • Remimazolam
  • Propofol
  • Acute Kidney Injury
  • Hemodynamic Stability
  • Hepatobiliary Surgery
  • Fluid Therapy
  • Fluid Therapy DURING SURGERY

Interventions

DRUG

Remimazolam (Byfavo)

TCI of remimazolam (0.3 - 1.5 mcg/ml)

DRUG

propofol

TCI of propofol (4.0 - 5.0 mg/mL)

Sponsors & Collaborators

  • Seoul National University Bundang Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-26
Primary Completion
2027-06-26
Completion
2028-06-26

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07674719 on ClinicalTrials.gov